Redeye thinks today’s deal means that both contracts with Enea's two major OS clients (Ericsson and ...
Redeye is encouraged by PANTAX phase Ib top-line data aligning with our expectations.
Redeye provides our initial take on Wyld Networks Q4 ’22 report, which contained no major surprises.
Redeye is encouraged to see that interest in the PFAS challenge increases with more sectors looking ...
I går meddelade Risk Intelligence att ett licensavtal slutits med DHL Freight för LandRisk Logistics...
Fiskars initiates employee consultations in its Iittala glass factory and retail network in Finland.
First oil at Dugong estimated in 2027 Promising Løvmeis exploration well to be drilled in Q3'24 Revi...
On March 29, 2023, Brain+ announced that the Company intends to carry out a preferential Rights Issu...
Q4 räddades av stark tillväxt inom Cirkulär Energi samt förvärvet av Miljöbelysning.
Embellence reports Q1'23 on 27 April Q1e net sales of SEK 176m, adj.
Administer’s H2 figures were slightly better than expected.
Q1 report due 21 April Q1'23e sales of SEK 462m, EBITA of SEK 61m Share trading at 7x-6x '23e-'25e E...
Solid growth ambitions released ahead of CMD tomorrowFY'23 guidance reiterated, as expectedOverall, ...
Relais acquires Adita Oy, a local distributor of spare parts and equipment for cars and marine use i...
In the recent management conference call to summarise the FY22 results, Scandion Oncology announced ...
With the second half of the year 2022 presented, we can state that OrderYOYO A/S (“OrderYOYO” or the...
Biovica has secured the initial European launch of DiviTum after signing Toro Medical Group as a com...
CombiGene har ingått samarbetsavtal för utveckling av läkemedel mot kroniska smärttillstånd.
(Correction: The Italian partner was earlier described as having financial difficulties.
Redeye comments on The Swedish Financial Supervisory Authority´s decision to initiate an investigati...
